BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models.

J. Ma, M. Lu, L. Chen, H. Geng, A. Kumar, M. Noviski, R. Rountree, C. Guiducci, J. Rubenstein. BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models. Hematological Oncology. 2023 Jun 9; 41(S2):546-547.

2023
https://researcherprofiles.org/profile/567651712

J. Ma, M. Lu, L. Chen, H. Geng, A. Kumar, M. Noviski, R. Rountree, C. Guiducci, J. Rubenstein